Streetbeat News

Stock Prices

AAPL

Wedbush analyst Daniel Ives has maintained an Outperform rating on Apple Inc. (NASDAQ:AAPL) and increased the price target from $240 to $250.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 4:12 pm

OXY

Occidental Petroleum's CEO announced that shareholders are expected to benefit from a 25% or higher free cash flow accretion due to CrownRock. The company also anticipates its Permian production to reach 750,000 barrels of oil and gas per day in 2024.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 4:11 pm

BMEA

CLSK

COGT

COIN

GIL

HIVE

MARA

RIOT

On Monday, several stocks experienced declines, with notable losses in the biotech sector and among companies associated with Bitcoin due to a pullback in its price. Cogent Biosciences and Biomea Fusion reported clinical trial data, resulting in significant drops in their share prices. Companies like CleanSpark, HIVE Digital Technologies, Riot Platforms, and Marathon Digital Holdings were affected by the Bitcoin price movement. Gildan Activewear announced a leadership change, and Tellurian updated its executive team.

Portfolio Pulse from Avi Kapoor

December 11, 2023 | 4:07 pm

SHAK

Shake Shack's stock price has seen an uptick following the company's reaffirmation of its fourth-quarter and full-year 2023 guidance. This reiteration may instill confidence in investors about the company's performance and outlook.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 4:05 pm

SPY

The New York Fed reported a decrease in consumer expectations for gasoline prices and rent over the next year. Expected gasoline prices dropped to 4.5% in November from 5% in October, while expected rent decreased to 8% from 9.1%, marking the lowest expectation for rent since January 2021.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 4:03 pm

COIN

Ex-Coinbase professionals have established a $500 million fund, C1, to acquire secondary shares in crypto firms like Animoca Brands and Chainalysis at discounts of 50% to 80%. The fund targets companies valued at $300 million or more and plans to invest $20 million to $50 million per deal. Animoca Brands, now valued at $7.8 billion, and Chainalysis, valued at $8.4 billion, are potential targets. The crypto market is showing signs of recovery, with Bitcoin crossing $40,000 and anticipation of a U.S.-regulated Bitcoin ETF and a Bitcoin network upgrade.

Portfolio Pulse from Murtuza Merchant

December 11, 2023 | 4:01 pm

APLS

Apellis Pharmaceuticals' shares have declined following the presentation of post hoc data that supported the long-term efficacy and safety of EMPAVELI for up to three years in adults with paroxysmal nocturnal hemoglobinuria.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 4:01 pm

AMGN

Amgen (NASDAQ:AMGN) is analyzed against its peers in the Biotechnology sector, showing a mixed valuation with a low P/E ratio, high P/B ratio, and low P/S ratio. Amgen's ROE, EBITDA, gross profit, and revenue growth are strong compared to the industry, but it has a higher debt-to-equity ratio, indicating potential financial risk.

Portfolio Pulse from Benzinga Insights

December 11, 2023 | 4:00 pm

AMAT

Applied Materials (AMAT) is analyzed against its competitors in the Semiconductors & Semiconductor Equipment industry. AMAT shows potential for growth with a lower P/E ratio than the industry average, suggesting undervaluation based on earnings. Its P/B ratio is higher, indicating possible overvaluation based on book value. The P/S ratio below the industry average suggests undervaluation based on sales. AMAT's ROE is above the industry average, indicating efficient profitability. Its EBITDA and gross profit are significantly higher than the industry average, demonstrating strong cash flow and earnings. Revenue growth is also higher, showing strong demand for its products. AMAT's lower debt-to-equity ratio compared to top peers suggests a strong financial position.

Portfolio Pulse from Benzinga Insights

December 11, 2023 | 4:00 pm

BSX

Over the past 10 years, Boston Scientific (NYSE:BSX) has produced an average annual return of 17.03%, outperforming the market by 7.1% on an annualized basis. A $100 investment in BSX a decade ago would be worth $483.55 today. The company's current market capitalization stands at $80.76 billion.

Portfolio Pulse from Benzinga Insights

December 11, 2023 | 4:00 pm